

# **2019 Future of Encephalopathy R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments**

<https://marketpublishers.com/r/2D04FE16BA9EN.html>

Date: February 2019

Pages: 60

Price: US\$ 2,199.00 (Single User License)

ID: 2D04FE16BA9EN

## **Abstracts**

The global demand for Encephalopathy treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Encephalopathy pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Encephalopathy pipeline companies from advancing their products into Phase 3 or Phase 4.

### **Encephalopathy Report Description-**

The 2019 pipeline study on Encephalopathy pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Encephalopathy pipeline compounds.

The Encephalopathy pipeline guide presents information on all active drugs currently being developed for Encephalopathy. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Encephalopathy pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Encephalopathy drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Encephalopathy product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Encephalopathy pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Encephalopathy pipeline report includes-

An overview of Encephalopathy disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Encephalopathy pipeline

Company wise list of Encephalopathy pipeline

Mechanism of Action wise Encephalopathy pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

## **REASONS TO BUY**

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Encephalopathy pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Encephalopathy pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Encephalopathy pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

## Contents

### 1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

### 2. GLOBAL ENCEPHALOPATHY PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

### 3. EXECUTIVE SUMMARY

- 3.1 Encephalopathy Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
  - 3.2.1 Pre-clinical
  - 3.2.2 Discovery
  - 3.2.3 Phase
  - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
  - 3.3.1 Phase
  - 3.3.2 Pre-registration
- 3.4 Companies involved in Encephalopathy pipeline, H1- 2019
- 3.5 Mechanism of Action wise Encephalopathy Pipeline Candidates

### 4 ALFASIGMA SPA ENCEPHALOPATHY PIPELINE DETAILS

- 4.1 AlfaSigma SpA Business Profile
- 4.2 AlfaSigma SpA Encephalopathy Drug Details
- 4.3 Drug Snapshot
  - 4.3.1 Originator
  - 4.3.2 Collaborator/Co-Developer
  - 4.3.3 Route of Administration
  - 4.3.4 Orphan Drug/Fast Track/Special Designation
  - 4.3.5 Geography
  - 4.3.6 Type of Molecular Entity
  - 4.3.7 Current Status

- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

## **5 BRAINREPAIR UG ENCEPHALOPATHY PIPELINE DETAILS**

- 5.1 BrainRepair UG Business Profile
- 5.2 BrainRepair UG Encephalopathy Drug Details
- 5.3 Drug Snapshot
  - 5.3.1 Originator
  - 5.3.2 Collaborator/Co-Developer
  - 5.3.3 Route of Administration
  - 5.3.4 Orphan Drug/Fast Track/Special Designation
  - 5.3.5 Geography
  - 5.3.6 Type of Molecular Entity
  - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

## **6 CELGENE CORP ENCEPHALOPATHY PIPELINE DETAILS**

- 6.1 Celgene Corp Business Profile
- 6.2 Celgene Corp Encephalopathy Drug Details
- 6.3 Drug Snapshot
  - 6.3.1 Originator
  - 6.3.2 Collaborator/Co-Developer
  - 6.3.3 Route of Administration
  - 6.3.4 Orphan Drug/Fast Track/Special Designation
  - 6.3.5 Geography
  - 6.3.6 Type of Molecular Entity
  - 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

## **7 CHIESI FARMACEUTICI SPA ENCEPHALOPATHY PIPELINE DETAILS**

- 7.1 Chiesi Farmaceutici SpA Business Profile
- 7.2 Chiesi Farmaceutici SpA Encephalopathy Drug Details
- 7.3 Drug Snapshot
  - 7.3.1 Originator
  - 7.3.2 Collaborator/Co-Developer
  - 7.3.3 Route of Administration
  - 7.3.4 Orphan Drug/Fast Track/Special Designation
  - 7.3.5 Geography
  - 7.3.6 Type of Molecular Entity
  - 7.3.7 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

## **8 COSMO PHARMACEUTICALS NV ENCEPHALOPATHY PIPELINE DETAILS**

- 8.1 Cosmo Pharmaceuticals NV Business Profile
- 8.2 Cosmo Pharmaceuticals NV Encephalopathy Drug Details
- 8.3 Drug Snapshot
  - 8.3.1 Originator
  - 8.3.2 Collaborator/Co-Developer
  - 8.3.3 Route of Administration
  - 8.3.4 Orphan Drug/Fast Track/Special Designation
  - 8.3.5 Geography
  - 8.3.6 Type of Molecular Entity
  - 8.3.7 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

## **9 FERRING INTERNATIONAL CENTER SA ENCEPHALOPATHY PIPELINE DETAILS**

- 9.1 Ferring International Center SA Business Profile
- 9.2 Ferring International Center SA Encephalopathy Drug Details

### 9.3 Drug Snapshot

#### 9.3.1 Originator

#### 9.3.2 Collaborator/Co-Developer

#### 9.3.3 Route of Administration

#### 9.3.4 Orphan Drug/Fast Track/Special Designation

#### 9.3.5 Geography

#### 9.3.6 Type of Molecular Entity

#### 9.3.7 Current Status

### 9.4 Drug Overview

### 9.5 Drug Mechanism of Action

### 9.6 Clinical/Pre-clinical Trial Details

### 9.7 Latest Drug Developments

## **10 GILEAD SCIENCES INC ENCEPHALOPATHY PIPELINE DETAILS**

### 10.1 Gilead Sciences Inc Business Profile

### 10.2 Gilead Sciences Inc Encephalopathy Drug Details

### 10.3 Drug Snapshot

#### 10.3.1 Originator

#### 10.3.2 Collaborator/Co-Developer

#### 10.3.3 Route of Administration

#### 10.3.4 Orphan Drug/Fast Track/Special Designation

#### 10.3.5 Geography

#### 10.3.6 Type of Molecular Entity

#### 10.3.7 Current Status

### 10.4 Drug Overview

### 10.5 Drug Mechanism of Action

### 10.6 Clinical/Pre-clinical Trial Details

### 10.7 Latest Drug Developments

## **11 GW PHARMACEUTICALS PLC ENCEPHALOPATHY PIPELINE DETAILS**

### 11.1 GW Pharmaceuticals Plc Business Profile

### 11.2 GW Pharmaceuticals Plc Encephalopathy Drug Details

### 11.3 Drug Snapshot

#### 11.3.1 Originator

#### 11.3.2 Collaborator/Co-Developer

#### 11.3.3 Route of Administration

#### 11.3.4 Orphan Drug/Fast Track/Special Designation



- 11.3.5 Geography
- 11.3.6 Type of Molecular Entity
- 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

## **12 KANNALIFE SCIENCES INC ENCEPHALOPATHY PIPELINE DETAILS**

- 12.1 KannaLife Sciences Inc Business Profile
- 12.2 KannaLife Sciences Inc Encephalopathy Drug Details
- 12.3 Drug Snapshot
  - 12.3.1 Originator
  - 12.3.2 Collaborator/Co-Developer
  - 12.3.3 Route of Administration
  - 12.3.4 Orphan Drug/Fast Track/Special Designation
  - 12.3.5 Geography
  - 12.3.6 Type of Molecular Entity
  - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

## **13 KNOPP BIOSCIENCES LLC ENCEPHALOPATHY PIPELINE DETAILS**

- 13.1 Knopp Biosciences LLC Business Profile
- 13.2 Knopp Biosciences LLC Encephalopathy Drug Details
- 13.3 Drug Snapshot
  - 13.3.1 Originator
  - 13.3.2 Collaborator/Co-Developer
  - 13.3.3 Route of Administration
  - 13.3.4 Orphan Drug/Fast Track/Special Designation
  - 13.3.5 Geography
  - 13.3.6 Type of Molecular Entity
  - 13.3.7 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action

13.6 Clinical/Pre-clinical Trial Details

13.7 Latest Drug Developments

## **14 MALLINCKRODT PLC ENCEPHALOPATHY PIPELINE DETAILS**

14.1 Mallinckrodt Plc Business Profile

14.2 Mallinckrodt Plc Encephalopathy Drug Details

14.3 Drug Snapshot

14.3.1 Originator

14.3.2 Collaborator/Co-Developer

14.3.3 Route of Administration

14.3.4 Orphan Drug/Fast Track/Special Designation

14.3.5 Geography

14.3.6 Type of Molecular Entity

14.3.7 Current Status

14.4 Drug Overview

14.5 Drug Mechanism of Action

14.6 Clinical/Pre-clinical Trial Details

14.7 Latest Drug Developments

## **15 MARINUS PHARMACEUTICALS INC ENCEPHALOPATHY PIPELINE DETAILS**

15.1 Marinus Pharmaceuticals Inc Business Profile

15.2 Marinus Pharmaceuticals Inc Encephalopathy Drug Details

15.3 Drug Snapshot

15.3.1 Originator

15.3.2 Collaborator/Co-Developer

15.3.3 Route of Administration

15.3.4 Orphan Drug/Fast Track/Special Designation

15.3.5 Geography

15.3.6 Type of Molecular Entity

15.3.7 Current Status

15.4 Drug Overview

15.5 Drug Mechanism of Action

15.6 Clinical/Pre-clinical Trial Details

15.7 Latest Drug Developments

## **16 MITHRA PHARMACEUTICALS SA ENCEPHALOPATHY PIPELINE DETAILS**

- 16.1 Mithra Pharmaceuticals SA Business Profile
- 16.2 Mithra Pharmaceuticals SA Encephalopathy Drug Details
- 16.3 Drug Snapshot
  - 16.3.1 Originator
  - 16.3.2 Collaborator/Co-Developer
  - 16.3.3 Route of Administration
  - 16.3.4 Orphan Drug/Fast Track/Special Designation
  - 16.3.5 Geography
  - 16.3.6 Type of Molecular Entity
  - 16.3.7 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

## **17 PAIRNOMIX LLC ENCEPHALOPATHY PIPELINE DETAILS**

- 17.1 Pairnomix LLC Business Profile
- 17.2 Pairnomix LLC Encephalopathy Drug Details
- 17.3 Drug Snapshot
  - 17.3.1 Originator
  - 17.3.2 Collaborator/Co-Developer
  - 17.3.3 Route of Administration
  - 17.3.4 Orphan Drug/Fast Track/Special Designation
  - 17.3.5 Geography
  - 17.3.6 Type of Molecular Entity
  - 17.3.7 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

## **18 PROTHERA BIOLOGICS INC ENCEPHALOPATHY PIPELINE DETAILS**

- 18.1 ProThera Biologics Inc Business Profile
- 18.2 ProThera Biologics Inc Encephalopathy Drug Details
- 18.3 Drug Snapshot
  - 18.3.1 Originator
  - 18.3.2 Collaborator/Co-Developer

- 18.3.3 Route of Administration
- 18.3.4 Orphan Drug/Fast Track/Special Designation
- 18.3.5 Geography
- 18.3.6 Type of Molecular Entity
- 18.3.7 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

## **19 SCIFLUOR LIFE SCIENCES LLC ENCEPHALOPATHY PIPELINE DETAILS**

- 19.1 SciFluor Life Sciences LLC Business Profile
- 19.2 SciFluor Life Sciences LLC Encephalopathy Drug Details
- 19.3 Drug Snapshot
  - 19.3.1 Originator
  - 19.3.2 Collaborator/Co-Developer
  - 19.3.3 Route of Administration
  - 19.3.4 Orphan Drug/Fast Track/Special Designation
  - 19.3.5 Geography
  - 19.3.6 Type of Molecular Entity
  - 19.3.7 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

## **20 SPHERIUM BIOMED SL ENCEPHALOPATHY PIPELINE DETAILS**

- 20.1 Spherium Biomed SL Business Profile
- 20.2 Spherium Biomed SL Encephalopathy Drug Details
- 20.3 Drug Snapshot
  - 20.3.1 Originator
  - 20.3.2 Collaborator/Co-Developer
  - 20.3.3 Route of Administration
  - 20.3.4 Orphan Drug/Fast Track/Special Designation
  - 20.3.5 Geography
  - 20.3.6 Type of Molecular Entity
  - 20.3.7 Current Status

- 20.4 Drug Overview
- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

## **21 SYNLOGIC INC ENCEPHALOPATHY PIPELINE DETAILS**

- 21.1 Synlogic Inc Business Profile
- 21.2 Synlogic Inc Encephalopathy Drug Details
- 21.3 Drug Snapshot
  - 21.3.1 Originator
  - 21.3.2 Collaborator/Co-Developer
  - 21.3.3 Route of Administration
  - 21.3.4 Orphan Drug/Fast Track/Special Designation
  - 21.3.5 Geography
  - 21.3.6 Type of Molecular Entity
  - 21.3.7 Current Status
- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details
- 21.7 Latest Drug Developments

## **22 TAKEDA PHARMACEUTICAL CO LTD ENCEPHALOPATHY PIPELINE DETAILS**

- 22.1 Takeda Pharmaceutical Co Ltd Business Profile
- 22.2 Takeda Pharmaceutical Co Ltd Encephalopathy Drug Details
- 22.3 Drug Snapshot
  - 22.3.1 Originator
  - 22.3.2 Collaborator/Co-Developer
  - 22.3.3 Route of Administration
  - 22.3.4 Orphan Drug/Fast Track/Special Designation
  - 22.3.5 Geography
  - 22.3.6 Type of Molecular Entity
  - 22.3.7 Current Status
- 22.4 Drug Overview
- 22.5 Drug Mechanism of Action
- 22.6 Clinical/Pre-clinical Trial Details
- 22.7 Latest Drug Developments

## **23 THERAPICON SRL ENCEPHALOPATHY PIPELINE DETAILS**

- 23.1 Therapicon Srl Business Profile
- 23.2 Therapicon Srl Encephalopathy Drug Details
- 23.3 Drug Snapshot
  - 23.3.1 Originator
  - 23.3.2 Collaborator/Co-Developer
  - 23.3.3 Route of Administration
  - 23.3.4 Orphan Drug/Fast Track/Special Designation
  - 23.3.5 Geography
  - 23.3.6 Type of Molecular Entity
  - 23.3.7 Current Status
- 23.4 Drug Overview
- 23.5 Drug Mechanism of Action
- 23.6 Clinical/Pre-clinical Trial Details
- 23.7 Latest Drug Developments

## **24 UMECRINE COGNITION AB ENCEPHALOPATHY PIPELINE DETAILS**

- 24.1 Umeocrine Cognition AB Business Profile
- 24.2 Umeocrine Cognition AB Encephalopathy Drug Details
- 24.3 Drug Snapshot
  - 24.3.1 Originator
  - 24.3.2 Collaborator/Co-Developer
  - 24.3.3 Route of Administration
  - 24.3.4 Orphan Drug/Fast Track/Special Designation
  - 24.3.5 Geography
  - 24.3.6 Type of Molecular Entity
  - 24.3.7 Current Status
- 24.4 Drug Overview
- 24.5 Drug Mechanism of Action
- 24.6 Clinical/Pre-clinical Trial Details
- 24.7 Latest Drug Developments

## **25 ZYNERBA PHARMACEUTICALS INC ENCEPHALOPATHY PIPELINE DETAILS**

- 25.1 Zynerva Pharmaceuticals Inc Business Profile
- 25.2 Zynerva Pharmaceuticals Inc Encephalopathy Drug Details
- 25.3 Drug Snapshot

- 25.3.1 Originator
- 25.3.2 Collaborator/Co-Developer
- 25.3.3 Route of Administration
- 25.3.4 Orphan Drug/Fast Track/Special Designation
- 25.3.5 Geography
- 25.3.6 Type of Molecular Entity
- 25.3.7 Current Status
- 25.4 Drug Overview
- 25.5 Drug Mechanism of Action
- 25.6 Clinical/Pre-clinical Trial Details
- 25.7 Latest Drug Developments

## **26. LATEST ENCEPHALOPATHY DRUG PIPELINE DEVELOPMENTS, 2019**

## **27. APPENDIX**

- 27.1 About Us
- 27.2 Sources and Methodology
- 27.3 Contact Information

## I would like to order

Product name: 2019 Future of Encephalopathy R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2D04FE16BA9EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2D04FE16BA9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



